Foundation Fighting Blindness funds gene therapy development
The grants will be allocated through the Foundation’s Translational Research Acceleration Program. One of the projects under the program involves the use of gene therapy to resurrect and
BioMarin Pharmaceutical and n-Lorem Foundation have entered an early-stage research collaboration and exclusive global licence agreement to develop an investigational antisense oligonucleotide (ASO) therapy for ReNU syndrome.
The new software addresses health care center’s interoperability challenges by eliminating data connection barriers between Hospital Information Systems (HIS), physician EMR systems, patient care devices, Emergency Department Systems